A blowout quarter across every business line has brokerages cheering, but the valuations is another story
India’s fluorine chemistry champion just delivered the kind of report card that would make any promoter beam. Navin Fluorine International crushed estimates across the board in the December quarter — revenue, EBITDA, and profit after tax all came in ahead of the Street. Every single business vertical grew by double digits. Margins expanded meaningfully. Order books are swelling.
But the stock well? Axis Securities said in a note “Stellar Performance, Valuation Fully Priced” and downgraded the stock from Buy to Hold with a target of Rs 6,950. HDFC Securities, however, retained its Buy rating with a higher target of Rs 7,260, arguing that the earnings inflection story has further room to run.
The Quarter That Beat
The numbers themselves are unambiguous. Revenue surged 47.2% year-on-year to Rs 8,924 million. EBITDA more than doubled, rising 109% to Rs 3,076 million. The EBITDA margin expanded a remarkable 1,017 basis points year-on-year to 34.5% — a level that overshoots even management’s own stated aspiration of approximately 30%.
HDFC Securities notes that “EBITDA and APAT was 10% and 7.6% above our estimates” — a clean beat on profitability that prompted the brokerage to raise its FY26 EPS estimate by 16.8%. Axis Securities echoed the surprise, noting that revenue, EBITDA, and PAT all came in ahead of expectations, leading to EBITDA estimate upgrades of 15%, 13%, and 12% for FY26 through FY28.
When two brokerages independently raise earnings estimates by double digits on the same quarter, the execution story speaks for itself.
The Fluorine Trifecta
What makes the Q3FY26 quarter particularly striking is that it wasn’t carried by a single segment. All three engines — High Performance Products, Specialty Chemicals, and CDMO — fired in unison.
HPP, accounting for 46% of revenue, delivered 35% year-on-year growth to Rs 4,120 million. Axis describes the performance as driven by “higher realisations and improved volumes amid a favourable pricing environment,” while HDFC Securities adds that the “R32 plant is almost running at full utilisation.” The recently commissioned AHF plant, HDFC notes, “will be majorly consumed internally” — a backward integration move that should structurally support margins in the refgas business.
The bigger prize lies ahead. Capex for incremental HFC capacity — up to 15,000 metric tonnes per annum of R32 — remains on track for commissioning in Q3FY27 and is expected to deliver peak annual revenues of Rs 600–825 crore, according to Axis
The Specialty Chemicals Breakout
If HPP was impressive, the Specialty Chemicals segment was the quarter’s showstopper. Revenue surged 60% year-on-year to Rs 3,540 million — representing 40% of the company’s topline. Axis calls it the segment’s “highest-ever quarterly performance.”
HDFC Securities attributes the surge to “improved utilization of Nectar plant” and notes that “management expects better offtake in volume over FY27 due to improved outlook and strong visibility.” The order pipeline, according to Axis, extends well into Q4FY26 and beyond, with the product portfolio expanding through both the scale-up of existing molecules and multiple new introductions.
Two capacity additions underpin the medium-term outlook. The Chemours project is expected to come online by Q1FY27. The debottlenecking of the MPP facility at Dahej, targeted for Q3FY27, could generate peak annual revenues of Rs 140–160 crore, per Axis estimates.
CDMO: The Long Game That’s Starting to Pay Off
For the bulls who have held Navin Fluorine through the lean years of CDMO investment, the December quarter offered vindication. The segment, contributing 14% of revenue, posted 61% year-on-year growth to Rs 1,240 million.
The quarter’s real significance, however, lies beyond the headline number. Navin completed validation and commenced commercial supplies from its cGMP4 Phase I facility — a unit built with a capex of Rs 1.6 billion — for a European client. Axis notes this provides “multi-year revenue visibility.” A scale-up order from another major European customer is lined up for Q4FY26.
HDFC Securities highlights the pipeline composition: “There is balance of 50/50% in late stage and early stage molecules in pipeline. Management expects readouts for more than one molecule in FY27, which can move toward commercialization.” That pipeline balance matters — late-stage molecules offer near-term revenue conversion, while early-stage ones ensure the business doesn’t hit a cliff in two or three years.
The brokerage frames the broader CDMO strategy as one focused on “select marquee global customers, with an emphasis on scaling revenues from commercial projects and late-stage molecules to secure more stable revenue streams.” In a global pharmaceutical landscape where Western companies are actively de-risking supply chains away from China, Navin’s fluorine-focused CDMO capabilities occupy an increasingly valuable niche.
The Road to EBITDA
EBITDA is expected to nearly triple from Rs 5.3 billion in FY25 to Rs 14.51 billion in FY29, while margins are projected to expand by 720 basis points to 29.9%, points out HDFC Securities. The drivers, the brokerage argues, are structural — “inflection in the CDMO business and improved realization in refgas business with support of backward integration in AHF.”
Management’s own stated target of approximately 30% EBITDA margins, with a band of plus or minus 200 basis points, already looks conservative given the 34.5% printed this quarter. NFIL’s strategy is to “deepen wallet share within its existing customer base by leveraging its established marketing network, broadening its product portfolio, and building on long-standing client relationships,” notes HDFC.
HDFC Securities has retained its Buy rating with a target of Rs 7,260, effectively arguing that the earnings upgrade cycle is not yet fully captured in the price. Its estimate revisions — FY26 EPS raised by 16.8%, FY27 by 2.5%, FY28 by 1.8% — suggest the near-term surprise was substantial, while the outer-year estimates remain relatively unchanged.
